API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-presents-the-first-dataset-of-bcl-2-inhibitor-lisaftoclax-in-patients-with-aml-demonstrating-favorable-efficacy-and-safety-302011941.html
https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-releases-encouraging-long-term-data-of-bcl-2-inhibitor-lisaftoclax-in-rr-cll-including-an-orr-of-73-3-302010995.html
https://www.prnewswire.com/news-releases/ash-2023--ascentage-pharma-to-present-results-from-three-clinical-studies-of-bcl-2-inhibitor-lisaftoclax-apg-2575-including-the-first-data-in-aml-and-mm-301976616.html
https://www.prnewswire.com/news-releases/ascentage-pharma-and-astrazeneca-enter-into-clinical-collaboration-on-the-registrational-phase-iii-study-of-bcl-2-inhibitor-lisaftoclax-in-combination-with-btk-inhibitor-acalabrutinib-in-treatment-naive-patients-with-first-line-cl-301956934.html
https://www.prnewswire.com/news-releases/ascentage-pharma-received-clearance-from-us-fda-to-proceed-with-global-registrational-phase-iii-clinical-trial-for-lisaftoclax-apg-2575-in-previously-treated-patients-with-cllsll-301894263.html
https://www.prnewswire.com/news-releases/ash-2022--ascentage-pharma-to-present-initial-data-of-bcl-2-inhibitor-lisaftoclax-apg-2575-in-combination-with-btk-inhibitors-for-the-treatment-of-rr-cllsll-including-an-orr-of-98-in-an-oral-report-at-the-ash-annual-meetin-301668295.html
https://www.prnewswire.com/news-releases/asco-2022--ascentage-pharma-releases-updated-data-demonstrating-lisaftoclaxs-apg-2575-therapeutic-potential-in-patients-with-rr-cllsll-301563282.html